Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates.
| Autor: | Oberoi HK; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Garralda E; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. egarralda@vhio.net.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Aug 15; Vol. 27 (16), pp. 4459-4461. Date of Electronic Publication: 2021 Jun 16. |
| DOI: | 10.1158/1078-0432.CCR-21-1353 |
| Abstrakt: | Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody-drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile. See related article by Johnson et al., p. 4521 . (©2021 The Authors; Published by the American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|